Replimune Has Significant Upside Potential, When Approved. But When Will That Be?

TG Therapeutics Should Increase Their Share Buyback Authorization Immediately

Commercial-Stage Biotech Is Undervalued. Q1 Earnings Recap, Part 2.

Who's Raising Full Year Guidance? Who's Affirming Full Year Guidance? Q1 Earnings Recap, Part 1.

Earnings Calendar For This Week, Near-Term Clinical Catalysts, YTD Performance, And More...

Q1 Earnings Season Preview: Commercial-Stage Biotechs

Short sellers are confident Cardiff Oncology will underwhelm - but are they right?

Ideaya is undervalued on their lead asset Darovasertib alone - you get the rest of the pipeline for free.

The Biotech Recession Shopping List

Free Post: March Performance Update

Edgewise's Sevasemten program meets the FDA's guidance for Accelerated Approval - and has a good chance of working in Phase 3.

I'm Still Struggling With Celcuity's Upcoming Phase 3 Readout - But It Has A Real Chance

Q4 2024 Earnings Call Recaps, Part 2

Q4 2024 Earnings Call Recaps, Part 1

Free Post: February Performance Update

Yes, Biotech Is Ailing. Here Are My Top Five Defensive Picks.

Quick Thoughts On Potential SpringWorks Acquistion And Position Sizing

Biotech Investors Are Completely Missing Something Right Now

Free Post: January Performance Update

JPMorgan Healthcare Conference Recap, Part 2 (Nine New Ideas)

JPMorgan Healthcare Conference Recap, Part 1

An Idea I Have Never Written About Before

What I'll Be Watching At The JPMorgan Healthcare Conference

The Case For Biotech

Free Post: My 2025 "No Trades" Model Portfolio